详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Elevated GSK3β expression predicts good prognosis in hepatocellular carcinoma.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic China [2]Dongguan Health School of Guangdong Province, Dongguan, Guangdong, People’s Republic China [3]Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical University, China.

出处：

关键词： GSK3β bioinformatic analysis hepatocellular carcinoma prognosis immunohistochemistry

摘要：

Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death worldwide. The role of GSK-3β in cancer progression is considered critical. However, the prognostic value of total GSK-3β protein levels in HCC remains undetermined. In this study, the expression and biologic significance of total GSK-3β in HCC were evaluated at mRNA and protein levels. We showed that GSK-3β mRNA levels were significantly upregulated in HCC tissues relative to the levels in the adjacent non-tumor tissues as recorded on the TCGA database (P < 0.001). Notably, GSK-3β protein levels were significantly downregulated in HCC tissues relative to those in the adjacent non-tumor tissues by immunohistochemistry (P < 0.001). We found that GSK-3β was negatively associated with the American Joint Committee on Cancer (AJCC) stage (P = 0.030) and positively correlated with good prognosis for HCC patients (P = 0.036). The data further indicated that GSK3β expression tended to be an independent prognostic marker for HCC after surgical resection (HR = 1.658, 95% CI 0.945-2.909, P = 0.078) and can potentially serve as a biomarker for the clinical diagnosis and prognosis of HCC. IJCEP Copyright © 2018.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 4 区医学

小类 | 4 区肿瘤学 4 区病理学

最新[2025]版：

大类 | 4 区医学

小类 | 4 区肿瘤学 4 区病理学

第一作者：

第一作者机构： [1]Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic China [2]Dongguan Health School of Guangdong Province, Dongguan, Guangdong, People’s Republic China

共同第一作者：

通讯作者：

通讯机构： [1]Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic China [3]Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical University, China. [*1]Cancer Center, Traditional Chinese Medicine-Integrated Hospital of Southern Medical University, 13 Shiliugang Road, Haizhu District, Guangzhou, Guangdong, People’s Republic China [*2]Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical University, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Low MYH9 expression predicts a good prognosis for hepatocellular carcinoma. [2]BLZF1 expression is of prognostic significance in hepatocellular carcinoma [3]Bioinformatics Analyses of Potential miRNA-mRNA Regulatory Axis in HBV-related Hepatocellular Carcinoma [4]Nuclear CD133 expression predicts poor prognosis for hepatocellular carcinoma. [5]Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma. [6]Prediction of the Ki-67 marker index in hepatocellular carcinoma based on CT radiomics features. [7]三种miRNA对肝癌预后预测的生物信息学分析模型 [8]Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma. [9]The Upregulation of Trophinin-Associated Protein (TROAP) Predicts a Poor Prognosis in Hepatocellular Carcinoma. [10]Quantitative acetylome analysis reveals histone modifications that may predict prognosis in hepatitis B-related hepatocellular carcinoma.